Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Programmed cell death protein 10 (PDCD10)
- Target
- PDCD10
- Molecular classification
- Other (scaffold/adaptor protein), Not classified as enzyme, receptor, transporter, channel, or transcription factor
01
Overview
Programmed cell death protein 10 (PDCD10) is a highly conserved, predominantly alpha-helical scaffold/adaptor protein that interacts with regulators of vascular structure and cell apoptosis. It is encoded by the *PDCD10* gene (also known as *CCM3*) and is essential for stabilizing blood vessels, limiting vascular leakage, and contributing to apoptosis pathways. Mutations in *PDCD10* are implicated in cerebral cavernous malformations, neurological conditions characterized by fragile, leaky blood vessels in the brain or spinal cord. PDCD10 participates in a protein complex with other CCM proteins, affects PI3K and VEGF signaling, and helps maintain vessel wall integrity, making it a subject of interest for therapeutics in vascular diseases, although no direct drugs target PDCD10 to date.
- Other names
- CCM3TFAR15Apoptosis-related protein 15Cerebral cavernous malformation 3 protein
02
Mechanism of action
Not applicable; no direct targeting therapies are currently recognized. Research mostly explores modulation of upstream/downstream effectors in the PI3K/AKT or VEGF signaling pathways
03
Biological functions
Vascular developmentApoptosis (cell death)Stabilization of blood vessel structure and limiting vascular leakageVEGF signaling pathway and protein interaction network assembly
04
Disease associations
Cerebral cavernous malformation (CCM, particularly type 3)Potential role in vascular disorders and hemorrhagic stroke through vessel pathology
05
Safety considerations
Loss of function or mutation leads to increased risk of cerebral cavernous malformation, with risk for hemorrhagic stroke and neurological impairment; no targeted therapy, thus no established safety concerns from direct targeting
06
Interacting drugs
None specifically approved or listed as interacting directly with PDCD10. Research on modulating associated pathways (such as VEGF or PI3K) is ongoing but no direct drugs reported as of this review
07
Biomarkers
Null (no known biomarkers for patient selection or monitoring efficacy; genetic testing for *PDCD10* mutations is used in CCM diagnosis)
Beyond the preview
Go deeper on Programmed cell death protein 10 (PDCD10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Programmed cell death protein 10 (PDCD10).